- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Skinvisible signs licensing agreement for two acne products
Las Vegas - Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
Las Vegas
- Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
The two prescription anti-acne products are formulated with Invisicare,a patented polymer delivery technology, with the active ingredients Clindamycin HCL and Retinoic Acid.
Related Videos
Quality of Life Impact: Supporting Patients With GPP
The Challenges of Diagnosis and Management of GPP
Melinda Gooderham, MD, MSc, FRCPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
Related Content
